№ lp_2_3_36712
File format: docx Character count: 24729 File size: 127 KB
Clinical shared care guideline outlining prescribing responsibilities, indications, contraindications, dosing regimens and monitoring arrangements for atomoxetine in the treatment of ADHD in children and adolescents within Greater Manchester NHS services.
Reference Number: ATOMOXETINE FOR THE TREATMENT OF ATTENTION HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
Version: 2.2
Replaces: 2.1
Issue date: 17.8.2017
Review date: 17.8.2020
Authors: Dr Prathiba Chitsabesan – Healthy Young Minds Consultant, Pennine Care NHS Foundation Trust; Arifa Raza Azmi – Clinical Pharmacist, Pennine Care NHS Foundation Trust
Approving body: Pathways and Guidelines Development Subgroup
Date approved by Pathways and Guidelines Development Subgroup: 13.7.2017
Note: Approving body Greater Manchester Medicines Management Group
Date approved by Greater Manchester Medicines Management Group: 17.8.2017
Organisation: Pennine Care NHS Foundation Trust
Region: Greater Manchester
Therapeutic area: Attention Deficit Hyperactivity Disorder (ADHD)
Medicine: Atomoxetine hydrochloride
Dosage forms: Hard capsules (10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg); 4mg/ml oral solution
Licensed population: Children and adolescents aged 6 years and above
Document type: Shared Care Guideline / Shared Care Protocol
Related documents: Summary of Product Characteristics; BNF
Indication: Severe or moderate ADHD impairment where psychological/behavioural measures alone are insufficient
Contraindications: Hypersensitivity to atomoxetine; concomitant use with MAOIs; severe cardiovascular or cerebrovascular disorders without specialist advice; narrow angle glaucoma; pheochromocytoma; hereditary fructose intolerance (oral solution)
Pregnancy and lactation status: Prescribing responsibility remains with the Specialist
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Methylphenidate, Dexamfetamine, Lisdexamfetamine and Atomoxetine for Treatment of ADHD in Adults: Shared Care Guidance
Year: 2026
Region: South Tyneside and Sunderland, UK
Topic: Adult Attention Deficit Hyperactivity Disorder (ADHD) treatment
Document type: Clinical guideline / Shared care protocol
Issuing body: South Tyneside and Sunderland Area Prescribing Committee
References: NICE Clinical Guideline 87, NICE Quality Standard 39
Target audience: Healthcare professionals managing adults with ADHD
Medications covered: Methylphenidate, Dexamfetamine, Lisdexamfetamine, Atomoxetine
Indications: ADHD in patients aged 18 years and over
Exclusions: Patients aged 5–17 years, patients under 5 years
Dosage forms: Tablets, capsules, oral solution
Administration instructions: Standard and modified-release regimens, including special administration for dysphagia or GI issues
Adverse effects: Appetite loss, insomnia, mood changes, cardiovascular effects, gastrointestinal effects, rare psychiatric effects
Disability Verification of Attention Deficit Hyperactivity Disorders
Note: Year
Region / City: Jacksonville, Florida
Subject: Disability Documentation
Document Type: Verification Form
Institution: University of North Florida
Author: Student Accessibility Center
Target Audience: Students with Attention Deficit Hyperactivity Disorder (ADHD)
Period of Validity: Current Documentation Required
Shared Care Guideline for Methylphenidate for Childhood and Adolescent Attention Deficit Hyperactivity Disorder (ADHD)
Year: 2017
Region / city: Greater Manchester, UK
Theme: ADHD, Medication, Shared Care Protocol
Document Type: Medical Guideline
Organization: Pennine Care NHS Foundation Trust, CMFT
Author: Dr. Prathiba Chitsabesan, Arifa Raza Azmi, Dr. Hilary Lloyd
Target Audience: Healthcare professionals
Approval Date: 13.7.2017 (Pathways and Guidelines Development Subgroup), 17.8.2017 (Greater Manchester Medicines Management Group)
Review Date: 17.8.2020
Date of Issue: 17.8.2017
Date of Replacement: 17.8.2017
Attention Deficit Hyperactivity Disorder: Utilisation Analysis
Year: 2021
Region / City: Australia
Topic: Drug Utilisation for ADHD
Document Type: Utilisation Analysis
Organization / Institution: Drug Utilisation Sub-Committee (DUSC)
Author: Not specified
Target Audience: Healthcare professionals, policymakers
Period of Validity: 2014-2020
Approval Date: June 2021
Date of Changes: Not specified
DEVON ADULT AUTISM AND ATTENTION DEFICIT HYPERACTIVITY DISORDER (DAANA) SERVICES Referral Form for General Practitioners
Note: Date
Region / city: Devon (excluding Plymouth)
Topic: Autism Spectrum Conditions, ADHD
Document type: Referral Form
Author: Devon Adult Autism and ADHD Service
Target audience: General Practitioners, Clinicians
Period of validity: N/A
Date of approval: N/A
Date of changes: N/A
Topics: 1782017 Atomoxetine Hyperactivity